Conference highlights

This promotional website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in Great Britain.

This promotional website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the UK and Ireland.

Report adverse events

Home

Medicines

Resources

Understanding HIV
HCP Tools
Podcasts in HIV

Events

Conference highlights
HIV Webinar Series

BIKTARVY® ▼(bictegravir 50mg/ emtricitabine 200mg/ tenofovir alafenamide 25mg tablets) PI

Prescribing information, details of adverse event reporting and indications can be found at the bottom of this page. BIKTARVY® is subject to additional monitoring ▼ in Great Britain; this requirement no longer applies in Ireland and Northern Ireland.

UK-BVY-0708 Date of preparation June 2024

This promotional website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in Great Britain.

This promotional website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the UK and Ireland.

BHIVA Spring Conference 2023

BHIVA Spring Conference 2024

BIKTARVY® ▼
(bictegravir 50mg/ emtricitabine 200mg/ tenofovir alafenamide 25mg tablets)

BIKTARVY® is subject to additional monitoring ▼ in Great Britain; this requirement no longer applies in Ireland and Northern Ireland.

DESCOVY®
(emtricitabine 200mg/tenofovir alafenamide 10mg tablets)

DESCOVY® is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).

DESCOVY® (emtricitabine 200mg/tenofovir alafenamide 25mg tablets)

DESCOVY® is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1 (HIV-1).

TRUVADA® (emtricitabine 200mg/tenofovir disoproxil 245mg tablets)

TRUVADA® is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.